myriad genetics inc (MYGN) Snapshot

The United States Supreme Court released its landmark decision in Association for Molecular Pathology et al. versus Myriad Genetics Inc. et al. The Court unanimously agreed that 'A naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated, but cDNA is patentable because it is not naturally occurring'. The decision helps to lay the foundation for continued research and application of diagnosis and treatment of diseases at the molecular level. 'AMP applauds the U.S. Supreme Court on their ground breaking, unanimous decision. There is no question that this is a critical and right decision for the future of medicine and science. Biomedical researchers, clinicians, and most importantly patients will see great benefit from this development'. In supporting AMP's position, the Court's detailed ruling noted, 'In this case. Myriad did not create anything. To be sure, it found an important and useful gene, but separating that gene from its surrounding genetic material is not an act of invention.

Myriad Genetics Inc. Presents at Goldman Sachs 34th Annual Global Healthcare Conference, Jun-11-2013 08:40 AM. Venue: Terranea Resort, Rancho Palos Verdes, California, United States. Speakers: Peter D. Meldrum, Chief Executive Officer, President and Director.

Myriad Genetics Inc. announced that AstraZeneca will use the company's BRACAnalysis test as a companion diagnostic to stratify patients in AstraZeneca's pivotal Phase 3 clinical studies for olaparib. Myriad has submitted an Investigational Device Exemption (IDE) with the U.S. Food and Drug Administration (FDA) for BRACAnalysis testing, which will allow the test to be used as a companion diagnostic to identify potential responders to olaparib therapy in the United States. While the company will be replacing the BRACAnalysis test with myRisk Hereditary Cancer(TM) for hereditary cancer testing, the company plans to offer BRACAnalysis testing as a companion diagnostic - following review by FDA - to help select patients who are likely to respond to poly ADP ribose polymerase (PARP) inhibitors, a novel, targeted class of promising cancer therapeutics. Olaparib is a novel, orally active PARP inhibitor that induces synthetic lethality in homozygous BRCA-deficient cells. Phase 2 clinical data presented at ASCO 2013 showed that patients with BRCA mutated ovarian cancers received the clinical benefit from maintenance treatment with olaparib, warranting further study. Based on these data, the company will collaborate with AstraZeneca to deliver BRAC testing for its pivotal clinical studies.